-
Skyline Therapeutics Reports Positive Preclinical Results for SKG0106 and SKG0201 Gene Therapies
•
Skyline Therapeutics, a Shanghai-based cell and gene therapy (CGT) developer, has announced encouraging preclinical study results for its AAV gene therapies, SKG0106 and SKG0201, targeting neovascular age-related macular degeneration (nAMD) and spinal muscular atrophy (SMA), respectively. SKG0106: A Novel AAV Therapy for nAMDSKG0106 is a self-developed novel AAV vector carrying…
-
Q1 2023 financial report: AstraZeneca leads innovation in China, Sanofi’s sales in China decline
•
Several multinational companies (MNCs) have released their Q1 2023 financials, showing a varied performance over the quarter. AstraZeneca’s China Innovation BoomAstraZeneca (AZ, NASDAQ: AZN) CEO Pascal Soriot warned that Europe is lagging behind China in fostering innovation and access to medicines. This statement came during the company’s Q1 2023 earnings…
-
CMS Receives NMPA Approval for Clinical Study of Tetravalent BsAb for nAMD
•
China Medical System Holdings (CMS; HKG: 0867) has announced that it has received approval from the National Medical Products Administration (NMPA) to proceed with a clinical study for its tetravalent bispecific antibody (BsAb) targeting vascular endothelial growth factor A (VEGFA) and angiopoietin 2 (ANG2) for intravitreal injection in the treatment…
-
Sirnaomics’ RV-1730 Receives FDA Clearance for Phase I COVID-19 Vaccine Booster Trial
•
Sirnaomics Ltd (HKG: 2257) has announced that it has received clearance from the United States Food and Drug Administration (FDA) for its Investigational New Drug (IND) application for a Phase I clinical trial of RV-1730, a SARS-CoV-2 vaccine booster candidate. Design of the Phase I Study for RV-1730The Phase I…
-
Jiangsu Hengrui’s Vunakizumab for Plaque Psoriasis Accepted for Review by NMPA
•
Jiangsu Hengrui Pharmaceutials Co., Ltd (SHA: 600276), a leading China-based pharmaceutical company, announced that the National Medical Products Administration (NMPA) has accepted its market filing for vunakizumab, an IL-17A monoclonal antibody (mAb), for the treatment of moderate to severe plaque psoriasis suitable for systemic therapy or phototherapy. Global IL-17A Products…
-
SynerK Achieves Milestone with First Patient Dosing in Phase I siRNA Clinical Trial
•
SynerK, a developer of RNA-targeted therapies with operations in Boston, US, and Beijing and Suzhou, China, has announced the completion of first patient dosing in its Phase I clinical study for an investigational small interfering RNA (siRNA). This marks the first time such a therapy has entered the clinical phase…
-
Roche’s Q1 2023 Report: 3% Dip in Revenues with Strong Growth in Pharmaceuticals
•
Roche (SWX: ROG), the Swiss pharmaceutical and diagnostics giant, reported a 3% year-on-year (YOY) decrease in turnover at constant exchange rates (CER) to CHF 15.3 billion (USD 17.2 billion) in its Q1 2023 report. The decline was attributed to the appreciation of the Swiss franc and a predicted drop in…
-
SinoMab’s SM03 Meets Primary Endpoint in Phase III Rheumatoid Arthritis Trial
•
Hong Kong-based biopharmaceutical company SinoMab BioScience Ltd (HKG: 3681) has announced that its Phase III clinical study for the CD22 monoclonal antibody (mAb) SM03, also known as suciraslimab, has successfully reached the primary endpoint in patients with rheumatoid arthritis (RA). Study Design and Efficacy of SuciraslimabThe randomized, double-blind, multi-center, placebo-controlled…
-
Junshi Biosciences’ RENOTORCH Study Meets Endpoints for RCC Treatment
•
Junshi Biosciences (HKG: 1877, SHA: 688180), a China-based biopharmaceutical company, has announced that its multi-center, randomized, open, positive-controlled Phase III RENOTORCH study has reached pre-set endpoints at the interim analysis stage. The study evaluates the programmed death-1 (PD-1) inhibitor Tuoyi (toripalimab) combined with axitinib for the treatment of moderate to…
-
Sihuan Pharmaceutical’s Birociclib Meets Primary Endpoint in Phase III Breast Cancer Study
•
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that its Phase III clinical study for birociclib, a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor, has successfully reached the primary endpoint in patients with HR+/HER2- advanced breast cancer that has progressed after previous endocrine therapy combined with fulvestrant. Positive Mid-Term Analysis…
-
CSPC Pharmaceutical’s Prusogliptin for Type 2 Diabetes Accepted for NMPA Review
•
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading China-based pharmaceutical company, announced that its market filing for the Category 1 drug prusogliptin, intended for the treatment of type 2 diabetes, has been accepted for review by the National Medical Products Administration (NMPA). Clinical Study Results and Efficacy of PrusogliptinA clinical…
-
Ocumension Therapeutics’ Zerviate Receives NMPA Priority Review for Ophthalmology Treatment
•
Ocumension Therapeutics (HKG: 1477), a leading Chinese ophthalmology specialist, has announced that its histamine H1 receptor-targeted drug, Zerviate (OT-1001), has been granted priority review status by the National Medical Products Administration (NMPA). Zerviate’s Origins and Market PresenceZerviate, originally developed by France-based pharmaceutical firm Nicox SA, is an innovative formulation of…
-
NMPA Mandates Label Updates for 11 Drug Varieties Including Black Box Warnings
•
The National Medical Products Administration (NMPA) has released 10 notifications regarding revisions to package inserts for 11 drug varieties, impacting 47 products in total. The updates include changes to sections on adverse reactions, contraindications, and precautions. Marketing Authorization Holders (MAHs) are mandated to update the package inserts and labels within…
-
Junshi Biosciences Submits Market Filings for PCSK9 mAb Ongericimab to NMPA
•
China’s Junshi Biosciences (HKG: 1877, SHA: 688180) has announced the submission of two market filings for its PCSK9 monoclonal antibody (mAb) ongericimab (JS002) for the treatment of primary hypercholesterolemia and mixed hyperlipidemia to the National Medical Products Administration (NMPA). Phase III and II Clinical Studies Support FilingsOngericimab is currently in…
-
Belief BioMed Completes Patient Dosing in Phase III Hemophilia B Gene Therapy Trial
•
Shanghai-based gene therapy specialist Belief BioMed Group (BBM) has announced the completion of patient dosing in its Phase III registrational clinical trial (CTR20212816) for BBM-H901, a gene therapy for hemophilia B. The therapy is developed and manufactured in-house by Shanghai Belief-Delivery Biomed Co., Ltd., a wholly owned subsidiary of BBM.…
-
Zhaoke Ophthalmology’s US Partner Visus Therapeutics Reports Positive Phase III Results
•
Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), announced that its US partner Visus Therapeutics Inc., has published positive topline results from the pivotal Phase III BRIO-I trial. BRIO-I Trial Success and Regulatory MilestonesThe BRIO-I trial successfully met the pre-specified primary study endpoints that were agreed…
-
Gan & Lee Pharmaceuticals Receives Marketing Approval for Insulin Glargine in Bolivia
•
Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced that it has received marketing approval from Bolivia’s State Agency of Drugs and Health Technologies (AGEMED) for its insulin glargine product, which comes in a pre-filled format. Insulin Glargine: A Long-Acting Insulin AnalogueInsulin glargine is a long-acting insulin…
-
GSK’s Cervarix Receives Approval for Two-Dose Schedule in China for Ages 9 to 14
•
The UK-based pharmaceutical giant GSK plc (NYSE: GSK) has announced the official market launch of a two-dose schedule for its bivalent recombinant human papillomavirus (HPV) vaccine, Cervarix (types 16 and 18), targeting girls aged 9 to 14 in China. Cervarix’s Approval History and Expansion in ChinaCervarix was first approved in…
-
Everest Medicines’ Nefecon for IgAN Approved for Clinical Use in Hainan
•
China-based Everest Medicines (HKG: 1952) has announced that Nefecon (delayed-release budesonide), the first-in-disease treatment for primary immunoglobulin A nephropathy (IgAN), has been approved by the Hainan Medical Products Administration for clinical use in Shanghai Ruijin Hospital’s Hainan subsidiary. This marks the beginning of a new treatment era for IgA nephropathy…
-
Zelgen Biopharmaceuticals’ ZG2001 Receives US FDA Clinical Trial Approval for Pan-KRAS Inhibitor
•
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266) has announced that it has received clinical trial approval from the US Food and Drug Administration (FDA) for its Category 1 product candidate, ZG2001. ZG2001 is an in-house discovered oral pan-KRAS mutation inhibitor under development for the treatment of KRAS mutant tumors. Prevalence…
